Yingqian Chen

机构：Zhejiang University · ORCID：0000-0001-5920-2801

发表论文 11 篇 · 总被引 658 次 · h-index 9

代表论文

Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy (2021 · Nature Chemical Biology · 被引 164)
Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2 (2018 · Blood · 被引 107)
Inhibition of M2-like macrophages by all-trans retinoic acid prevents cancer initiation and stemness in osteosarcoma cells (2019 · Acta Pharmacologica Sinica · 被引 100)
Advances in targeted therapy for osteosarcoma based on molecular classification (2021 · Pharmacological Research · 被引 90)
Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARα and eradicates acute promyelocytic leukemia cells (2021 · Acta Pharmaceutica Sinica B · 被引 65)
Advances in differentiation therapy for osteosarcoma (2019 · Drug Discovery Today · 被引 56)